Human Beta-defensin 1 in Vitiligo

Estimation of Tissue Level of Human Beta-defensin 1 (HBD-1) in Vitiligo Before and After Narrowband UVB Phototherapy: a Case-control Study

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03832751

Enrollment

Registered

2019-02-06

Start date

2019-03-31

Completion date

2019-12-31

Last updated

2019-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Brief summary

There is a need to know the role of human beta defensin-1 in vitiligo pathogenesis and the probability of finding newer and effective therapy for vitiligo in the future.

Interventions

OTHERskin biopsy before and after NB-UVB phototherapy

skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients with non-segmental vitiligo. * Both genders. * Age more than 18 years old. * New cases or cases not receiving any treatment for at least 3 months prior to the study.

Exclusion criteria

* Universal or segmental vitiligo. * Any contraindication to phototherapy treatment. * History of autoimmune diseases or other systemic diseases. * Any other skin disease.

Design outcomes

Primary

Measure	Time frame
Tissue levels of human beta-defensin 1 before and after NB-UVB phototherapy	6 months to 1 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026